CLESNUVO Trademark

Trademark Overview


On Wednesday, September 27, 2023, a trademark application was filed for CLESNUVO with the United States Patent and Trademark Office. The USPTO has given the CLESNUVO trademark a serial number of 98200268. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Thursday, October 24, 2024. This trademark is owned by Rosemont Pharmaceuticals Limited. The CLESNUVO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and medical preparations for patients suffering from dysphagia and conditions requiring medication in liquid form for the treatment of viral, bacterial, parasitic and fungal diseases and infections; oral liquid medicines for the treatment of viral, bacterial, parasitic and fungal diseases and infections; drugs for medical purposes in the nature of medicines for the treatment of viral, bacterial, parasitic and fungal diseases and infections; substances, drugs, medicines and medical preparations, namely, drug delivery agents consisting of compounds in the form of oral liquid medicines, oral suspensions, dispersible and soluble tablets, and powders to be consumed in liquid form, that facilitate the delivery of a wide range of pharmaceuticals; substances, drugs, medicines and medical preparations, namely, drug delivery agents consisting of compounds in the form of oral liquid medicines, oral suspensions, dispersible and soluble tablets, and powders to be consumed in liquid f...
clesnuvo

General Information


Serial Number98200268
Word MarkCLESNUVO
Filing DateWednesday, September 27, 2023
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateThursday, October 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and medical preparations for patients suffering from dysphagia and conditions requiring medication in liquid form for the treatment of viral, bacterial, parasitic and fungal diseases and infections; oral liquid medicines for the treatment of viral, bacterial, parasitic and fungal diseases and infections; drugs for medical purposes in the nature of medicines for the treatment of viral, bacterial, parasitic and fungal diseases and infections; substances, drugs, medicines and medical preparations, namely, drug delivery agents consisting of compounds in the form of oral liquid medicines, oral suspensions, dispersible and soluble tablets, and powders to be consumed in liquid form, that facilitate the delivery of a wide range of pharmaceuticals; substances, drugs, medicines and medical preparations, namely, drug delivery agents consisting of compounds in the form of oral liquid medicines, oral suspensions, dispersible and soluble tablets, and powders to be consumed in liquid form, that facilitate the delivery of anti-infective agents, antineoplastic agents, cardiovascular agents, central nervous system agents, coagulation modifiers, gastrointestinal agents, genitourinary tract agents, psychotherapeutic agents and metabolic agents

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 11, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRosemont Pharmaceuticals Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLeeds LS119XE

Trademark Events


Event DateEvent Description
Saturday, September 30, 2023NEW APPLICATION ENTERED
Wednesday, October 11, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, May 20, 2024ASSIGNED TO EXAMINER
Tuesday, June 4, 2024NON-FINAL ACTION WRITTEN
Tuesday, June 4, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 4, 2024NON-FINAL ACTION E-MAILED
Wednesday, July 17, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 24, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 24, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 24, 2024ASSIGNED TO LIE